MedTrace Logo

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

NCT05250050 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 388

Last updated 2022-03-18

No results posted yet for this study

Summary

This multicenter randomized controlled clinical trial was conducted to compare the eradication efficacy and health economic benefits of individualized regimens based on HP drug resistance mutation gene detection (multiple PCR method), individualized regimens based on HP traditional drug sensitivity testing (E-test method) and empirical regimens in the Helicobacter pylori treatment.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Esomeprazole

20mg bid

DRUG

Bismuth potassium citrate

0.6g bid

DRUG

Metronidazole

0.4g qid

DRUG

Clarithromycin

0.5g bid

DRUG

Levofloxacin

0.5g qd

DRUG

Amoxicillin

1g bid

DRUG

Tetracycline

0.5g qid

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Hong Gao, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2022-12-30
Completion
2023-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05250050 on ClinicalTrials.gov